148 related articles for article (PubMed ID: 25586555)
1. A survey of patient preferences for oral antihyperglycemic therapy in patients with type 2 diabetes mellitus.
Hauber AB; Tunceli K; Yang JC; Gantz I; Brodovicz KG; Alexander CM; Davies MJ; Radican L
Diabetes Ther; 2015 Mar; 6(1):75-84. PubMed ID: 25586555
[TBL] [Abstract][Full Text] [Related]
2. Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes.
Hauber AB; Han S; Yang JC; Gantz I; Tunceli K; Gonzalez JM; Brodovicz K; Alexander CM; Davies M; Iglay K; Zhang Q; Radican L
Patient Prefer Adherence; 2013; 7():937-49. PubMed ID: 24086104
[TBL] [Abstract][Full Text] [Related]
3. A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes.
Hauber AB; Nguyen H; Posner J; Kalsekar I; Ruggles J
Curr Med Res Opin; 2016; 32(2):251-62. PubMed ID: 26549576
[TBL] [Abstract][Full Text] [Related]
4. Patient Preference for Once-Weekly Dosing in Type 2 Diabetes Mellitus in Japan.
Sen R; Shields AL; Atsuda K
J Health Econ Outcomes Res; 2016; 4(1):55-66. PubMed ID: 37663012
[No Abstract] [Full Text] [Related]
5. Patient Preferences for Attributes of Type 2 Diabetes Mellitus Medications in Germany and Spain: An Online Discrete-Choice Experiment Survey.
Mansfield C; Sikirica MV; Pugh A; Poulos CM; Unmuessig V; Morano R; Martin AA
Diabetes Ther; 2017 Dec; 8(6):1365-1378. PubMed ID: 29101681
[TBL] [Abstract][Full Text] [Related]
6. Patients' preferences for once-daily oral versus once-weekly injectable diabetes medications: The REVISE study.
Boye K; Ross M; Mody R; Konig M; Gelhorn H
Diabetes Obes Metab; 2021 Feb; 23(2):508-519. PubMed ID: 33140575
[TBL] [Abstract][Full Text] [Related]
7. Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK.
Gelhorn HL; Stringer SM; Brooks A; Thompson C; Monz BU; Boye KS; Hach T; Lund SS; Palencia R
Diabetes Obes Metab; 2013 Sep; 15(9):802-9. PubMed ID: 23464623
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study.
Qin L; Chen S; Flood E; Shaunik A; Romero B; de la Cruz M; Alvarez C; Grandy S
Diabetes Ther; 2017 Apr; 8(2):321-334. PubMed ID: 28155131
[TBL] [Abstract][Full Text] [Related]
9. What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences.
Mühlbacher A; Bethge S
Eur J Health Econ; 2016 Dec; 17(9):1125-1140. PubMed ID: 26682548
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom.
Qin L; Chen S; Flood E; Shaunik A; Romero B; de la Cruz M; Alvarez C; Grandy S
Diabetes Ther; 2017 Apr; 8(2):335-353. PubMed ID: 28236271
[TBL] [Abstract][Full Text] [Related]
11. Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK.
Gelhorn HL; Poon JL; Davies EW; Paczkowski R; Curtis SE; Boye KS
Patient Prefer Adherence; 2015; 9():1611-22. PubMed ID: 26635470
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the Preferences and Willingness-to-Pay for Oral Antidiabetic Drugs Among Patients with Type 2 Diabetes Mellitus in China: A Discrete Choice Experiment.
Chuang LH; Zhang H; Hong T; Xie S
Patient; 2024 Apr; ():. PubMed ID: 38642244
[TBL] [Abstract][Full Text] [Related]
13. Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment.
Fifer S; Rose J; Hamrosi KK; Swain D
BMC Health Serv Res; 2018 Aug; 18(1):675. PubMed ID: 30165844
[TBL] [Abstract][Full Text] [Related]
14. Patient preferences for treatment in type 2 diabetes: the Italian discrete-choice experiment analysis.
Marchesini G; Pasqualetti P; Anichini R; Caputo S; Memoli G; Ponzani P; Resi V; Rizzo M; Serviddio G; Zanette G
Acta Diabetol; 2019 Mar; 56(3):289-299. PubMed ID: 30306406
[TBL] [Abstract][Full Text] [Related]
15. Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences.
Mohamed AF; Zhang J; Johnson FR; Lomon ID; Malvolti E; Townsend R; Ostgren CJ; Parhofer KG
Diabetes Metab; 2013 Oct; 39(5):397-403. PubMed ID: 23880594
[TBL] [Abstract][Full Text] [Related]
16. Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan.
Gelhorn HL; Bacci ED; Poon JL; Boye KS; Suzuki S; Babineaux SM
Patient Prefer Adherence; 2016; 10():1337-48. PubMed ID: 27524889
[TBL] [Abstract][Full Text] [Related]
17. What Is Valued Most by Patients With Type 2 Diabetes Mellitus When Selecting Second-Line Antihyperglycemic Medications in China.
Liu S; Liu J; Yu Y; Si L; Tang C; Liu Z; Chen Y
Front Pharmacol; 2021; 12():802897. PubMed ID: 35002736
[No Abstract] [Full Text] [Related]
18. Preferences for Patients with Type 2 Diabetes Mellitus for Medications in Shandong Province, China: A Discrete Choice Experiment.
Lv Y; Ren R; Tang C; Song K; Li S; Wang H
Patient Prefer Adherence; 2022; 16():2335-2344. PubMed ID: 36046499
[TBL] [Abstract][Full Text] [Related]
19. Changing Patients' Treatment Preferences and Values with a Decision Aid for Type 2 Diabetes Mellitus: Results from the Treatment Arm of a Randomized Controlled Trial.
Bailey RA; Shillington AC; Harshaw Q; Funnell MM; VanWingen J; Col N
Diabetes Ther; 2018 Apr; 9(2):803-814. PubMed ID: 29536425
[TBL] [Abstract][Full Text] [Related]
20. Preferences for Attributes of Sodium Oxybate Treatment: A Discrete Choice Experiment in Patients with Narcolepsy.
Dubow J; Avidan AY; Corser B; Athavale A; Seiden D; Kushida C
Patient Prefer Adherence; 2022; 16():937-947. PubMed ID: 35422617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
